サンプル分類1
Tesamorelin
- 2mg*10vials USD 41.00
- 5mg*10vials USD 80.00
- 10mg*10vials USD 160.00
- 20mg*10vials USD 248.00
参考価格です。お支払いの前にコンシェルジュが金額を確認します。
5.0 / 5 · 2283 件注文の送信後、コンシェルジュへ連絡するときは注文番号をお知らせください。
製品の特長
FDA approves treatment specifically for reducing visceral fat
製品紹介
Tesamorelin is a synthetic 44-amino acid peptide analog that resembles growth hormone-releasing hormone (GHRH). It stimulates the release of endogenous growth hormone and increases IGF-1 levels, thereby promoting lipolysis and providing metabolic benefits. Tesamorelin has been approved by the FDA for the reduction of visceral adipose tissue in individuals with HIV-associated lipodystrophy.
注意事項
Reconstitution: Add 2.5 mL of bacteriostatic water to each 5 mg vial → concentration becomes 2.0 mg/mL
Standard daily dose: 2 mg (2000 mcg) once daily
Easy measurement: 1 unit = 0.01 mL = 20 mcg
使い方
1. Draw 2.5 mL of bacteriostatic water using a sterile syringe.
2. Inject slowly along the inner wall of the vial; avoid the formation of bubbles.
3. Gently swirl until dissolved (do not shake).
4. Label the vial and store refrigerated at 2–8°C, protected from light.
5. Once reconstituted with bacteriostatic water, use within 7 days.
保存方法
Lyophilized: Store at 2–8°C
Reconstituted with bacteriostatic water: Store refrigerated at 2–8°C; use within 7 days
Do not freeze the reconstituted solution; avoid repeated freeze-thaw cycles
レビュー
5.0 / 5
2283 件
最新100件を表示しています。
-
★★★★★
VX3•••••••952B
韓国
2026-10-12 05:39
Delivery was on time. The item was as described. A reliable delivery.
-
★★★★★
VX5•••••••D7F2
米国
2026-10-12 01:46
The handover was smooth. The order form and the parcel agreed. Pleased with how it was sent.
-
★★★★★
VX8•••••••EC65
その他
2026-10-11 21:54
The parcel was packed securely. The batch note was readable. A reliable delivery.
-
★★★★★
VX2•••••••8267
オランダ
2026-10-11 18:01
The outer carton was solid. The contents were undamaged. Simple and correct.
-
★★★★★
VX3•••••••C07F
オーストラリア
2026-10-11 14:08
The shipment was handled carefully. The storage note was easy to follow. Simple and correct.
-
★★★★★
VXC•••••••E1D3
日本
2026-10-11 10:16
The listing photo matched the parcel. The label matches the listing. This was a solid order.
-
★★★★★
VXF•••••••4D9D
オランダ
2026-10-11 06:23
The parcel was packed securely. The vial matched the description. A reliable delivery.
-
★★★★★
VXF•••••••E68F
英国
2026-10-11 02:30
The inner pack was tidy. The spec line matches what I received. Clear from start to finish.
-
★★★★★
VX4•••••••5A0F
カナダ
2026-10-10 22:38
The address on the box was correct. The label was easy to read. The experience was smooth.
-
★★★★★
VX2•••••••ACD3
その他
2026-10-10 18:45
The carton was dry and closed. The closure was clean. I would order again.
購入者レビュー
注文時の注文番号と電話番号を入力してください。この商品を含む注文と両方が一致する必要があります。
ほかの掲載商品
サンプル分類1
Cagrilintide
Cagrilintide is a long-acting, acylated amylin analogue—a pancreatic hormone—designed for once-weekly subcutaneous injection. It activates central amylin receptors, promoting satiety, slowing gastric emptying, and reducing food intake. In Phase 2 and Phase 3 clinical trials, cagrilintide induced dose-dependent weight loss, with side effects primarily being gastrointestinal in nature.
参考価格USD 113.00
サンプル分類1
CJC-1295+IPA(CP10)
This formulation combines CJC-1295 (without DAC)—a modified growth hormone-releasing hormone (GHRH) analog—with Ipamorelin, a selective growth hormone secretagogue (GHS). CJC-1295 (without DAC) produces a sustained, dose-dependent increase in GH and IGF-1 levels, while Ipamorelin selectively stimulates GH release without increasing ACTH or cortisol.
参考価格USD 116.00
サンプル分類1
Retatrutide
Retatrutide is an investigational triple-receptor agonist peptide (targeting GLP-1, GIP, and glucagon receptors) currently under development for the treatment of obesity and type 2 diabetes. Phase II clinical trials have demonstrated significant weight loss, with patients in the high-dose group achieving a weight reduction of up to 24% over 48 weeks. This educational program outlines a once-weekly subcutaneous administration regimen, incorporating a gradual dose-escalation approach to minimize gastrointestinal side effects.
参考価格USD 45.00
サンプル分類1
Tirzepatide
Tirzepatide is a dual incretin receptor agonist composed of 39 amino acids. It activates both GLP-1 and GIP receptors, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite. With a half-life of approximately 5 days, it is convenient to administer via a once-weekly subcutaneous injection. Clinical trials have demonstrated that tirzepatide offers superior efficacy in terms of glycemic control and weight loss compared to selective GLP-1 receptor agonists.
参考価格USD 40.00